Eli Lilly has reportedly agreed to acquire three vaccine developers in deals worth up to nearly $4bn in combined value.
The purchases would mark a significant strategic diversification for a company that has built its recent dominance on weight-loss and diabetes therapies.
The acquisitions of Curevo, LimmaTech Biologics and Vaccine Co signal a concerted move by the Indianapolis-based drugmaker into the infectious disease prevention space — a therapeutic area that had not previously been a core focus for the company.
Lilly's expansion comes on the back of surging revenues from its GLP-1 portfolio, with the company deploying that cash through a sustained acquisition programme spanning multiple disease areas.
Shingles, bacterial pathogens and the Epstein-Barr virus
Each of the three targets addresses a distinct unmet medical need.
Curevo is developing a vaccine to prevent shingles in adults, with its shareholders set to receive up to $1.5bn in cash, including upfront and milestone payments.
LimmaTech Biologics, which is developing vaccines targeting bacterial pathogens, will be acquired for up to $780m, again, including upfront and milestone-contingent payments.
The third deal centres on Vaccine Co, which is advancing a candidate against the Epstein-Barr virus — a highly prevalent and contagious infection increasingly linked to longer-term health complications.
Lilly has agreed to pay up to $1.55bn for that acquisition, including upfront and potential clinical and commercial milestone payments.
Strategic significance for the sector
The triple deal is notable not only for its scale but for its span across vaccine modalities and pathogen classes.
For the pharmaceutical manufacturing sector, the transactions may raise questions around production scale-up, cold chain logistics and regulatory pathway complexity, particularly given that each candidate remains in development and milestone payments are contingent on clinical progress.
Lilly joins a broader industry trend of large pharma companies using strong balance sheets to secure vaccine pipeline assets, with infectious disease prevention increasingly viewed as a long-term growth category.
The news was reported in the Wall Street Journal earlier on Tuesday.